Difelikefalin Impurity 16 is a difelikefalin-related peptide arising as a minor process or degradation product. Subtle sequence changes modify hydrophobic balance, folding, and retention time. Researchers characterize it to ensure impurity limits and method selectivity. Applications include synthetic-route optimization, stress-testing, and structure-property correlation work.
CAT No: Z10-101-224
Synonyms/Alias:1-(N2-D-phenylalanyl-D-phenylalanyl-D-leucyl-N6-(tert-butyl)-D-lysyl)-4-aminopiperidine-4-carboxylic acid
Difelikefalin impurity 16 is a synthetic peptide derivative structurally related to the parent compound difelikefalin, a selective kappa opioid receptor agonist. As an isolated impurity, it represents a minor peptide sequence variant or degradation product that may arise during the synthesis, storage, or formulation of difelikefalin. The analytical and functional study of such peptide impurities is essential in peptide research, particularly for quality control, regulatory compliance, and understanding the behavior of peptide-based pharmaceuticals. Its presence and characterization provide insight into the chemical integrity, stability, and synthetic pathway of the parent peptide, making it a valuable reference material for both research and industrial applications.
Impurity profiling: In the context of peptide drug development and manufacturing, difelikefalin impurity 16 serves as a critical standard for impurity profiling. By enabling the precise identification and quantification of this specific impurity, researchers and quality control laboratories can ensure the accuracy and reliability of analytical methods such as high-performance liquid chromatography (HPLC) and mass spectrometry. The availability of this impurity as a reference compound aids in establishing impurity thresholds and supports the development of robust quality assurance protocols for peptide products.
Analytical method validation: The use of difelikefalin impurity 16 is instrumental in validating analytical methods designed to detect and quantify peptide-related substances. Laboratories employ this impurity to assess the sensitivity, specificity, and reproducibility of their analytical workflows, ensuring that minor sequence variants or byproducts are reliably identified. This process is essential for the implementation of standardized testing procedures, particularly in environments where regulatory documentation and batch release testing are required.
Degradation pathway elucidation: Studying this impurity allows researchers to map the degradation pathways of difelikefalin under various stress conditions, such as exposure to heat, light, or oxidative environments. By understanding how and when difelikefalin impurity 16 forms, scientists can optimize peptide synthesis and storage conditions to minimize unwanted byproducts. This knowledge directly informs formulation strategies and enhances the overall stability profile of peptide-based pharmaceuticals.
Peptide synthesis optimization: The occurrence and characterization of difelikefalin impurity 16 provide valuable feedback to synthetic chemists seeking to refine peptide manufacturing processes. By systematically analyzing the formation of this impurity during solid-phase peptide synthesis or purification steps, researchers can adjust reaction conditions, reagent selection, or purification protocols to improve yield and purity. This iterative optimization contributes to more efficient and scalable production of high-quality peptide compounds.
Reference material for regulatory submissions: In the preparation of regulatory dossiers for peptide therapeutics, the availability of well-characterized impurities such as difelikefalin impurity 16 is crucial. Detailed data on the structure, formation, and analytical detectability of this impurity support comprehensive impurity profiling and risk assessment required by regulatory agencies. Its inclusion as a reference standard enhances the credibility and completeness of documentation submitted for investigational or commercial peptide products, thereby facilitating regulatory review and approval processes.
1. Myotropic activity of allatostatins in tenebrionid beetles
3. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs
5. TMEM16F and dynamins control expansive plasma membrane reservoirs
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More